Elin Borgen
Overview
Explore the profile of Elin Borgen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1747
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andresen N, Rossevold A, Borgen E, Schirmer C, Gilje B, Garred O, et al.
Mol Oncol
. 2024 Jul;
PMID: 38978352
Immune checkpoint inhibitors (ICIs) have been introduced in breast cancer (BC) treatment and better biomarkers are needed to predict benefit. Circulating tumor cells (CTCs) are prognostic in BC, but knowledge...
2.
Dorraji E, Borgen E, Segura-Pena D, Rawat P, Smorodina E, Dunn C, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230782
The expression of human epidermal growth factor receptor 2 (HER2) is a key classification factor in breast cancer. Many breast cancers express isoforms of HER2 with truncated carboxy-terminal fragments (CTF),...
3.
Lien T, Ohnstad H, Lingjaerde O, Vallon-Christersson J, Aaserud M, Sveli M, et al.
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885228
The PAM50 gene expression subtypes and the associated risk of recurrence (ROR) score are used to predict the risk of recurrence and the benefits of adjuvant therapy in early-stage breast...
4.
Engebraaten O, Yau C, Berg K, Borgen E, Garred O, Berstad M, et al.
Nat Commun
. 2021 Nov;
12(1):6427.
PMID: 34741021
HER2 is a predictive biomarker for HER2-targeted therapeutics. For antibody-drug conjugates (ADCs; e.g., trastuzumab emtansine (T-DM1)), HER2 is utilized as a transport gate for cytotoxic agents into the cell. ADC...
5.
Hartkopf A, Brucker S, Taran F, Harbeck N, von Au A, Naume B, et al.
Eur J Cancer
. 2021 Jul;
154:128-137.
PMID: 34265505
Purpose: Presence of disseminated tumour cells (DTCs) in the bone marrow (BM) has been described as a surrogate of residual disease in patients with early breast cancer (EBC). PADDY (Pooled...
6.
Haugen M, Lingjaerde O, Hedenfalk I, Garred O, Borgen E, Loman N, et al.
JCO Precis Oncol
. 2021 May;
5.
PMID: 34036235
Purpose: Antiangiogenic therapy using bevacizumab has proven effective for a number of cancers; however, in breast cancer (BC), there is an unmet need to identify patients who benefit from such...
7.
Kruger K, Silwal-Pandit L, Wik E, Straume O, Stefansson I, Borgen E, et al.
Sci Rep
. 2021 Feb;
11(1):3388.
PMID: 33564016
A subset of breast cancer patients benefits from preoperative bevacizumab and chemotherapy, but validated predictive biomarkers are lacking. Here, we aimed to evaluate tissue-based angiogenesis markers for potential predictive value...
8.
Hugenschmidt H, Labori K, Borgen E, Brunborg C, Schirmer C, Thomas Seeberg L, et al.
Cancers (Basel)
. 2021 Jan;
13(3).
PMID: 33513877
In patients with presumed pancreatic ductal adenocarcinoma (PDAC), biomarkers that may open for personalised, risk-adapted treatment are lacking. The study analysed the impact of CTCs-presence on the patterns of recurrence...
9.
Tinholt M, Stavik B, Tekpli X, Garred O, Borgen E, Kristensen V, et al.
Oncoimmunology
. 2021 Jan;
9(1):1824644.
PMID: 33457104
Background: Factor (F) V is an essential cofactor in blood coagulation, however, expression in breast tumors has also been linked to tumor aggressiveness and overall survival. The specific role of...
10.
Helland T, Naume B, Hustad S, Bifulco E, Kvaloy J, Saetersdal A, et al.
Mol Oncol
. 2020 Nov;
15(4):957-967.
PMID: 33252186
Low steady-state levels of active tamoxifen metabolites have been associated with inferior treatment outcomes. In this retrospective analysis of 406 estrogen receptor-positive breast cancer (BC) patients receiving adjuvant tamoxifen as...